Investment Banking
The annual EP Vantage Medtech 2016 in Review report offers analysis and expert commentary on M&A deals venture financing, initial public offerings and FDA approvals in the medtech sector during 2016.
London Managing Director Gareth Down is quoted extensively and is the sole commentator throughout the report.
Stay up-to-date with the latest William Blair news and insights
The 220,000+ companies that contract with the Department of Defense will soon face a significantly expanded regulatory framework—known as CMMC 2.0—designed to thwart increased cyber threats and secure the defense industrial base.
Read moreWilliam Blair acted as the exclusive financial advisor to TT medic GmbH and its shareholders in connection with entering a partnership with Trill Impact.
Read moreWilliam Blair initiated research coverage of First Advantage Corporation (FA $15.32), a leading global provider of technology-enabled background screening products.
Read moreInformation contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.
For disclosure information, please visit www.williamblair.com/disclosures
